Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics

Nature Reviews Cancer

Volumn 7, Issue 10, 2007, Pages 750-762

  Jares, Pedro ^a   Colomer, Dolors ^a   Campo, Elias ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BMS 345541; BORTEZOMIB; CURCUMIN; CYCLIN D1; EVEROLIMUS; FLAVOPIRIDOL; GELDANAMYCIN; GX 15 070; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OBATOCLAX; OBLIMERSEN; ON 013100; ON 01370; PD 0332991; PROTEASOME INHIBITOR; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN INHIBITOR; RITUXIMAB; ROSCOVITINE; SULFONE DERIVATIVE; TEMSIROLIMUS; THALIDOMIDE; TRAIL DR4 ANTIBODY; TRAIL DR5 ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER GENETICS; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOGENETICS; DNA DAMAGE; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MANTLE CELL LYMPHOMA; METAPHASE; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; CYCLIN D1; CYCLINS; DNA DAMAGE; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; GENE EXPRESSION; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENES; TRANSLOCATION, GENETIC;

EID: 34648824397     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2230     Document Type: Review

References (140)

1. Campo, E., Raffeld, M. & Jaffe, E. S. Mantle-cell lymphoma. Semin. Hematol. 36, 115-127 (1999).
2. Nodit, L., Bahler, D. W., Jacobs, S. A., Locker, J. & Swerdlow, S. H. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum. Pathol. 34, 1030-1034 (2003).
3. Espinet, B. et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Hum. Pathol. 36, 1232-1237 (2005).
4. Orchard, J. et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101, 4975-4981 (2003). Recognized a subset of MCL patients with long survival, some of them without need for treatment.
5. Raffeld, M. & Jaffe, E. S. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78, 259-263 (1991).
6. Kuppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nature Rev. Cancer 5, 251-262 (2005).
7. Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nature Rev. Cancer 7, 233-245 (2007).
8. Jaffe, E. S., Harris, N. L., Stein, H. & Vardiman, J. W. World Health Organziation classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon (2001).
9. Welzel, N. et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res. 61, 1629-1636 (2001).
10. Roix, J. J., McQueen, P. G., Munson, P. J., Parada, L. A. & Misteli, T. Spatial proximity of translocationprone gene loci in human lymphomas. Nature Genet. 34, 287-291 (2003).
11. Nanba, K., Jaffe, E. S., Braylan, R. C., Soban, E. J. & Berard, C. Alkline phosphatase-positive malignant lymphomas. A subset of B-cell lymphomas. Am. J. Clin. Pathol. 68, 535-542 (1977).
12. Banks, P. M. et al. Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am. J. Surg. Pathol. 16, 637-640 (1992). Defines MCL as a clinicopathological entity associated with the t(11;14) translocation.
13. Dono, M., Cerruti, G. & Zupo, S. The CD5 + B-cell. Int. J. Biochem. Cell Biol. 36, 2105-2111 (2004).
14. Camacho, F. I. et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 101, 4042-4046 (2003).
15. Kienle, D. et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 102, 3003-3009 (2003).
16. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-1854 (1999).
17. Crespo, M. et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764-1775 (2003).
18. Carreras, J. et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J. Pathol. 205, 507-513 (2005).
19. Bosch, F. et al. PRAD-1/Cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 84, 2726-2732 (1994).
20. de Boer, C. J., van Krieken, J. H. J. M., Kluin-Nelemans, H. C., Kluin, P. M. & Schuuring, E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 10, 1833-1840 (1995). References 19 and 20 showed that cyclin D1 overexpression in lymphoid neoplasms was a highly specific characteristic for MCL.
21. Bigoni, R. et al. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 13, 797-802 (1996).
22. Monteil, M., Callanan, M., Dascalescu, C., Sotto, J. J. & Leroux, D. Molecular diagnosis of t(11;14) in mantle cell lymphoma using two- colour interphase fluorescence in situ hybridization. Br. J. Haematol. 93, 656-660 (1996).
23. Vaandrager, J. W. et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 88, 1177-1182 (1996). Showed that virtually all MCL carry the t(11;14) translocation.
24. Seto, M. et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 7, 1401-1406 (1992).
25. de Boer, C. J. et al. Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization. Oncogene 15, 1599-1603 (1997).
26. Komatsu, H. et al. A variant chromosome translocation at 11q13 identifying PRAD1/Cyclin D1 as the bcl-1 gene. Blood 84, 1226-1231 (1994).
27. Rimokh, R. et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 83, 1871-1875 (1994).
28. Wiestner, A. et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109, 4599-4606 (2007).
29. Rosenwald, A. et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3, 185-197 (2003). Showed the global expression profile of MCL and recognized a subset of these tumours negative for cyclin D1.
30. Sander, B. et al. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int. J. Cancer 117, 418-430 (2005).
31. Hosokawa, Y., Joh, T., Maeda, Y., Arnold, A. & Seto, M. Cyclin D1/PRAD1/BCL-1 alternative transcript [B] protein product in B-lymphoid malignancies with t(11;14)(q13;q32) translocation. Int. J. Cancer 81, 616-619 (1999).
32. Betticher, D. C. et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005-1011 (1995).
33. Alt, J. R., Cleveland, J. L., Hannink, M. & Diehl, J. A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14, 3102-3114 (2000).
34. Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
35. Solomon, D. A. et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J. Biol. Chem. 278, 30339-30347 (2003).
36. Hunter, T. & Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79, 573-582 (1994).
37. Ewen, M. E. et al. Fuctional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73, 487-497 (1993).
38. Jares, P. et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am. J. Pathol. 148, 1591-1600 (1996).
39. Pinyol, M. et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 109, 5422-5429 (2007).
40. Quintanilla-Martinez, L. et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 101, 3181-3187 (2003).
41. Qi, C. F. et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk. Res. 30, 153-163 (2006).
42. Chiarle, R. et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95, 619-626 (2000).
43. Fu, M., Wang, C., Li, Z., Sakamaki, T. & Pestell, R. G. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145, 5439-5447 (2004).
44. Coqueret, O. Linking cyclins to transcriptional control. Gene 299, 35-55 (2002).
45. Fu, K. et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106, 4315-4321 (2005).
46. Salaverria, I. et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J. Clin. Oncol. 25, 1216-1222 (2007).
47. Gesk, S. et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 108, 1109-1110 (2006).
48. Hinds, P. H., Dowdy, S., Eaton, E. N., Arnold, A. & Weinberg, R. A. Function of a human cyclin gene as an oncogene. Proc. Natl Acad. Sci. USA 91, 709-713 (1994).
49. Bodrug, S. E. et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 13, 2124 (1994).
50. Lovec, H., Grzeschiczek, A., Kowalski, M.-B. & Moroy, T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B- cell lymphomas in transgenic mice. EMBO J. 13, 3487-3495 (1994).
51. Gladden, A. B., Woolery, R., Aggarwal, P., Wasik, M. A. & Diehl, J. A. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25, 998-1007 (2006).
52. Marzec, M. et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108, 1744-1750 (2006).
53. Krieger, S., Gauduchon, J., Roussel, M., Troussard, X. & Sola, B. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer 6, 238 (2006).
54. Hirt, C., Schuler, F., Dolken, L., Schmidt, C. A. & Dolken, G. Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. Blood 104, 904-905 (2004).
55. Wlodarska, I., Pittaluga, S., Hagemeijer, A., Wolf-Peeters, C. & Van Den, B. H. Secondary chromosome changes in mantle cell lymphoma. Haematologica 84, 594-599 (1999).
56. Bea, S. et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93, 4365-4374 (1999). Showed that MCL had a high number of secondary chromosomal imbalances with a distinctive profile different from other lymphoid neoplasms.
57. Bentz, M. et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27, 285-294 (2000).
58. Allen, J. E. et al. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br. J. Haematol. 116, 291-298 (2002).
59. Kohlhammer, H. et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104, 795-801 (2004).
60. Rubio-Moscardo, F. et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105, 4445-4454 (2005).
61. Schraders, M. et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 105, 1686-1693 (2005).
62. Flordal, T. E. et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk. Res. 31, 1227-1238 (2007).
63. Tagawa, H. et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24, 1348-1358 (2005).
64. Rinaldi, A. et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132, 303-316 (2006).
65. Salaverria, I., Perez-Galan, P., Colomer, D. & Campo, E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91, 11-16 (2006).
66. Ott, G. et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89, 1421-1429 (1997). Showed that MCL, particularly pleomorphic variants, have frequent tetraploid clones.
67. Vaishampayan, U. N., Mohamed, A. N., Dugan, M. C., Bloom, R. E. & Palutke, M. Blastic mantle cell lymphoma associated with Burkitt-type translocation and hypodiploidy. Br. J. Haematol. 115, 66-68 (2001).
68. Au, W. Y. et al. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica 85, 1225-1227 (2000).
69. Nielaender, I., Martin-Subero, J. I., Wagner, F., Martinez-Climent, J. A. & Siebert, R. Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia 20, 904-905 (2006).
70. Fitzgibbon, J. et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 65, 9152-9154 (2005).
71. Camps, J. et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk. Res. 30, 923-934 (2006).
72. Drexler, H. G. & MacLeod, R. A. Mantle cell lymphoma-derived cell lines: unique research tools. Leuk. Res. 30, 911-913 (2006).
73. Fernandez, V., Hartmann, E., Ott, G., Campo, E. & Rosenwald, A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J. Clin. Oncol. 23, 6364-6369 (2005).
74. Perez-Galan, P. et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107, 257-264 (2006). Showed that the proteasome inhibitor bortezomib induces apoptosis through generation of ROS and NOXA overexpression.
75. Perez-Galan, P., Roue, G., Villamor, N., Campo, E. & Colomer, D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109, 4441-4449 (2007).
76. Rudolph, C. et al. Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. Cancer Genet. Cytogenet. 153, 144-150 (2004).
77. Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89, 272-280 (1997).
78. Dreyling, M. H. et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 57, 4608-4614 (1997).
79. Hutter, G. et al. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. Genes Chromosomes Cancer 45, 203-210 (2006).
80. Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 164-168 (1999).
81. Hernandez, L. et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res. 65, 2199-2206 (2005).
82. Zukerberg, L. R. et al. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood 88, 268-276 (1996).
83. Hernandez, L. et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87, 3351-3359 (1996).
84. Greiner, T. C. et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87, 4302-4310 (1996).
85. Hartmann, E. et al. Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309. Haematologica 92, 574-575 (2007).
86. Stilgenbauer, S. et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 94, 3262-3264 (1999).
87. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nature Rev. Cancer 3, 155-168 (2003).
88. Schaffner, C., Idler, I., Stilgenbauer, S., Dohner, H. & Lichter, P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc. Natl Acad. Sci. USA 97, 2773-2778 (2000).
89. Camacho, E. et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99, 238-244 (2002).
90. Fang, N. Y. et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc. Natl Acad. Sci. USA 100, 5372-5377 (2003). References 88-90 showed frequent mutations of ATM in MCL compared to other lymphomas that were related to more complex karyotypes and present in the germline of occasional MCL patients.
91. Gronbaek, K. et al. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood 100, 1430-1437 (2002).
92. Starczynski, J. et al. Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. Am. J. Pathol. 163, 423-432 (2003).
93. Kuppers, R. & Dalla-Favera, R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20, 5580-5594 (2001).
94. Zhou, B. B. & Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439 (2000).
95. Tort, F. et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100, 4602-4608 (2002).
96. Hangaishi, A. et al. Mutations of Chk2 in primary hematopoietic neoplasms. Blood 99, 3075-3077 (2002).
97. Tort, F. et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19, 112-117 (2005).
98. Pinyol, M. et al. Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. Int. J. Cancer 119, 2768-2774 (2006).
99. Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P. & Ford, R. J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171, 88-95 (2003).
100. Rudelius, M. et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108, 1668-1676 (2006).
101. Roue, G. et al. Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J. Immunol. 178, 1923-1930 (2007).
102. Brody, J. & Advani, R. Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev. Oncol. Hematol. 58, 257-265 (2006).
103. Schulz, H. et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 99, 706-714 (2007).
104. Witzig, T. E. Current treatment approaches for mantle-cell lymphoma. J. Clin. Oncol. 23, 6409-6414 (2005).
105. O'connor, O. A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J. Clin. Oncol. 23, 6429-6436 (2005).
106. Kouroukis, C. T. et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 1740-1745 (2003).
107. Lin, T. S., Howard, O. M., Neuberg, D. S., Kim, H. H. & Shipp, M. A. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk. Lymphoma 43, 793-797 (2002).
108. Lacrima, K. et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann. Oncol. 16, 1169-1176 (2005).
109. Park, I. W., Reddy, M. V., Reddy, E. P. & Groopman, J. E. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene 26, 5635-5642 (2007).
110. Fisher, R. I. et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 24, 4867-4874 (2006).
111. Goy, A. et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 667-675 (2005).
112. O'connor, O. A. et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23, 676-684 (2005). References 110-112 showed the response of MCL patients to the new proteasome inhibitor bortezomib.
113. Reed, J. C. & Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood 106, 408-418 (2005).
114. Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324-1337 (2007).
115. Cho-Vega, J. H. et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 35, 1095-1100 (2004).
116. Khoury, J. D. et al. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J. Pathol. 199, 90-97 (2003).
117. Zhai, D., Jin, C., Satterthwait, A. C. & Reed, J. C. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 13, 1419-1421 (2006).
118. Kelley, S. K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333-339 (2004).
119. MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. & Cohen, G. M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65, 11265-11270 (2005).
120. Fanale, M. A. & Younes, A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67, 333-350 (2007).
121. Tolcher, A. W. et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25, 1390-1395 (2007).
122. Haritunians, T. et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21, 333-339 (2007).
123. Hipp, S. et al. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90, 1433-1434 (2005).
124. Shishodia, S., Amin, H. M., Lai, R. & Aggarwal, B. B. Curcumin (diferuloylmethane) inhibits constitutive NF-?B activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70, 700-713 (2005).
125. Guidoboni, M. et al. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res. 65, 587-595 (2005).
126. O'connor, O. A. et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24, 166-173 (2006).
127. Sakajiri, S. et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 33, 53-61 (2005).
128. Gallinari, P., Di, M. S., Jones, P., Pallaoro, M. & Steinkuhler, C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 17, 195-211 (2007).
129. Marks, P. A. & Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnol. 25, 84-90 (2007).
130. INK4A. Leukemia 17, 1914-1915 (2003).
131. Kaufmann, H. et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104, 2269-2271 (2004).
132. Martinez, A. et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am. J. Pathol. 164, 501-510 (2004).
133. Altieri, D. C. Coupling apoptosis resistance to the cellular stress response: the IAP-Hsp90 connection in cancer. Cell Cycle 3, 255-256 (2004).
134. Georgakis, G. V., Li, Y. & Younes, A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br. J. Haematol. 135, 68-71 (2006).
135. Swerdlow, S. H. et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am. J. Pathol. 113, 181-197 (1983).
136. Bosch, F. et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 82, 567-575 (1998).
137. Tiemann, M. et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br. J. Haematol. 131, 29-38 (2005).
138. Thelander, E. F. et al. Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. Mod. Pathol. 18, 331-339 (2005).
139. Limpens, J. et al. Lymphoma-associated translocation t(14;18) in blood B-cells of normal individuals. Blood 85, 2528-2536 (1995).
140. Cong, P. et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 99, 3376-3382 (2002).